Biorce is a pioneering medtech company dedicated to revolutionizing drug development through artificial intelligence. Founded in 2024 and headquartered in Barcelona, Spain, Biorce addresses the inefficiencies in clinical trials, such as startup delays and costly protocol amendments, which often hinder timely access to life-saving treatments. By leveraging AI, Biorce aims to streamline the clinical trial process, reducing both time and costs associated with bringing new therapies to market. Key Features and Functionality: - Jarvis AI Platform: Biorce's flagship product, Jarvis, is an AI-powered assistant designed specifically for clinical research. Trained on data from over 500,000 clinical studies, Jarvis assists in protocol design, feasibility assessments, regulatory alignment, endpoint selection, and patient recruitment. - Real-Time Recommendations: Jarvis provides real-time, evidence-backed insights, enabling pharmaceutical companies, biotech firms, and clinical research organizations (CROs) to make informed decisions throughout the trial process. - Predictive Analytics: The platform predicts site performance and flags potential delays before they occur, allowing for proactive adjustments and minimizing operational errors. Primary Value and Solutions: Biorce's AI-driven solutions tackle the root causes of delays and inefficiencies in clinical trials, which can cost time, money, and ultimately lives. By cutting through complexity and shortening timelines, Biorce improves outcomes for patients. The platform has demonstrated the ability to reduce protocol amendments by up to 50% and shorten clinical timelines by as much as 25%. For large pharmaceutical sponsors, this translates into significant annual savings and, more importantly, quicker access to therapies for patients in need. In summary, Biorce's innovative use of AI in clinical trials enhances efficiency, reduces costs, and accelerates the delivery of new treatments, ultimately benefiting both the healthcare industry and patients worldwide.